Novel cinnamic acid-based <i>N</i>-benzyl pyridinium analogs: potent dual cholinesterase inhibitors with neuroprotective properties for Alzheimer's disease.
Ontology highlight
ABSTRACT: This study reports the design and synthesis of a novel series of cinnamic acid-based analogs bearing an N-benzyl pyridinium moiety against Alzheimer's disease (AD), aiming at dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), alongside neuroprotective effects. A total of 15 derivatives were synthesized, among which compound 7b exhibited the most potent dual inhibition (AChE IC50 = 0.89 µM; BChE IC50 = 0.11 µM), and significant neuroprotection against H2O2-induced oxidative stress in SH-SY5Y cells, with no cytotoxicity under the tested concentration. Structure-activity relationship (SAR) analysis revealed that small electron-withdrawing substituents (e.g. ortho-fluoro, methyl) enhanced inhibitory activity, whereas meta and para substitutions generally reduced potency. Enzyme kinetics also determined compound 7b to be a competitive inhibitor of AChE (K i = 0.49 µM). Furthermore, molecular docking and molecular dynamics simulations identified stable binding interactions in the active sites of AChE and BChE. All these findings support the potential of these compounds as effective multi-target-directed ligands (MTDLs) for AD, displaying coordinated inhibition of cholinesterase, neuroprotection, and low toxicity.
SUBMITTER: Esmkhani M
PROVIDER: S-EPMC12908697 | biostudies-literature | 2026 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA